Granata Bio has secured a strategic investment from global women’s health pharma company Gedeon Richter, which includes the acquisition of a significant equity stake and board representation. While financial terms were not disclosed, the agreement establishes a strategic partnership between the two companies and includes a binding term sheet for the co-development of BEMFOLA, Richter’s recombinant follicle stimulating hormone (FSH), for the U.S. market.
“We’re proud to partner with Gedeon Richter, an organization whose global footprint and manufacturing excellence perfectly complement Granata Bio’s strengths in the U.S. market. This collaboration brings together the best of both companies: deep therapeutic expertise, operational agility, and a shared commitment to improving access to fertility care,” said Evan Sussman, CEO and Co-Founder of Granata Bio.
As part of the agreement, the companies have also signed a royalty purchase agreement for Granata’s proprietary human menopausal gonadotropin (hMG) program, aligning their long-term commercial interests in the fertility sector.
“FSH is the most prescribed gonadotropin by volume and represents a cornerstone of ovarian stimulation treatment. The addition of BEMFOLA to our pipeline significantly strengthens our portfolio, providing coverage across all major IVF product categories,” said Stephen Medeiros, Chief Operating Officer of Granata Bio.
The partnership combines Granata’s U.S. market expertise, relationships with key opinion leaders, and clinical development capabilities with Richter’s global scale, manufacturing infrastructure, and established presence in reproductive health markets worldwide.
The investment follows Granata Bio’s recent acquisition of Oviva Therapeutics. Founded in 2018, Granata’s pipeline includes multiple fertility therapies across various drug classes aimed at addressing unmet needs in reproductive medicine.
